Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

12 Months Ended

Jul. 31, 2022

	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	74,428		$	32,643			—			—		$	107,071

Operating costs and expenses:
Cost of revenues		45,891			19,213			—			—			65,104
Research and development		1,329			2,383		$	55			—			3,767
Selling, general and administrative		26,173			11,604			—		$	10,241			48,018
Legal and related expenses		254			186			—			5,249			5,689
Legal settlements		—			(500	)		—			—			(500	)
Total operating costs and expenses		73,647			32,886			55			15,490			122,078

Operating income (loss)		781			(243	)		(55	)		(15,490	)		(15,007	)

Other income (expense)
Interest		(19	)		45			—			133			159
Other		77			4			—			(1,272	)		(1,191	)
Foreign exchange loss		—			(2,222	)		—			—			(2,222	)
Income (loss)before taxes	$	839		$	(2,416	)	$	(55	)	$	(16,629	)	$	(18,261	)

Depreciation and amortization included above	$	1,711		$	813			—		$	303		$	2,827

Share-based compensation included above:
Selling, general and administrative		190			22			—			1,270			1,482
Cost of sales		8			6			—			—			14
Total	$	198		$	28			—		$	1,270		$	1,496

Capital expenditures	$	929		$	1,915			—		$	628		$	3,472

	Clinical Laboratory Services			Life Sciences Products		Therapeutics			Other			Consolidated
Revenues	$	86,984		$	30,747	$	—		$	—		$	117,731

Operating costs and expenses:
Cost of revenues		48,179			15,975		—			—			64,154
Research and development		615			2,559		78			—			3,252
Selling, general and administrative		26,028			11,015		62			7,800			44,905
Legal and related expenses		264			25		—			4,439			4,728
Total operating costs and expenses		75,086			29,574		140			12,239			117,039

Operating income (loss)		11,898			1,173		(140	)		(12,239	)		692

Other income (expense)
Interest		(17	)		37		—			(12	)		8
Other		(18	)		7		—			6,916			6,905
Foreign exchange gain		—			270		—			—			270
Income (loss) before taxes	$	11,863		$	1,487	$	(140	)	$	(5,335	)	$	7,875

Depreciation and amortization included above	$	1,609		$	756	$	—		$	288		$	2,653

Share-based compensation included in above:
Selling, general and administrative		33			102		—		$	679			814
Cost of sales		93			—		—			—			93
Total	$	126		$	102	$	—		$	679		$	907

Capital expenditures	$	3,352		$	752	$	—		$	332		$	4,436

	Clinical Laboratory Services			Life Sciences Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	47,964		$	26,561		—			—		$	74,525
Grant income		1,496			—		—			—			1,496
Total		49,460			26,561		—			—			76,021
Operating costs and expenses:
Cost of revenues		38,855			13,396		—			—			52,251
Research and development		1,509			2,190	$	749			—			4,448
Selling, general and administrative		23,533			10,485		—		$	8,942			42,960
Legal and related expenses		211			2		—			6,516			6,729
Total operating costs and expenses		64,108			26,073		749			15,458			106,388

Operating (loss) income		(14,648	)		488		(749	)		(15,458	)		(30,367	)

Other income (expense)
Interest		(36	)		56		—			434			454
Other		45			13		—			430			488
Foreign exchange gain		—			905		—			—			905
(Loss) income before taxes	$	(14,639	)	$	1,462	$	(749	)	$	(14,594	)	$	(28,520	)

Depreciation and amortization included above	$	1,553		$	964		—		$	263		$	2,780

Share-based compensation included above:
Selling, general and administrative		57			74		—			756			887
Cost of sales		46			—		—			—			46
Total	$	103		$	74		—		$	756		$	933

Capital expenditures	$	1,811		$	322		—		$	37		$	2,170

Net Services, Products and Grant revenues from unaffiliated customers, Year ended July 31,	2022		2021		2020
United States	$	94,209	$	102,601	$	64,284
Europe		8,568		10,386		7,720
Asia Pacific		4,294		4,744		4,017
Total	$	107,071	$	117,731	$	76,021